Clinical trials: Amyloid Beta Protein
Alzheimer Disease, Alzheimer Dementia
Study to Evaluate Amyloid in Blood and Imaging Related to Dementia
The purpose of this study is to determine how well a blood test can detect amyloid beta, a protein involved in Alzheimer's disease.
- Trial name
- SEABIRD (NCT03899844)
- Testing
- Blood collection, PiB PET/MRI, and cognitive testing
- Where
- United States
- Volunteers
- 1,122 people
- Sponsor
- Washington University School of Medicine
Alzheimer's Disease
Amyloid-beta PET Imaging With 18F-92 in Alzheimer's Disease
Alzheimer's disease is a neurodegenerative disease. Numerous studies have reported that β-amyloid (Aβ) is an important marker for the diagnosis of AD.
- Trial name
- NCT04926272
- Testing
- 18F-92
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Alzheimer Disease
Study of AV-1959D, an Amyloid Beta Vaccine
Phase 1 clinical trial of AV-1959 amyloid-β vaccine for Alzheimer's disease (AD).
- Trial name
- NCT05642429
- Testing
- AV-1959D
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Institute for Molecular Medicine
Stress Reaction, Stress Physiology
Acute Plasma Abeta Responses to Stress
Research has shown that activation of the sympathetic nervous system for extended periods or during certain times in life can increase the risk for Alzheimer's disease.
- Trial name
- NCT05521919
- Testing
- Sympathetic Nervous System Activation, No-stress
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Amyloid Beta Protein
Escitalopram Effects on CSF Amyloid Beta
Alzheimers disease (AD) is a devastating illness, estimated to affect 5 million patients in the United States alone and projected to increase dramatically over the next decades as the population ages unless preventive measures…
- Trial name
- NCT02161458
- Testing
- Escitalopram 20mg for 2 weeks, Escitalopram 20mg for 8 weeks, Escitalopram 30mg for 8 weeks
- Where
- 2 sites in United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Mild to Moderate Alzheimer's Disease
A 28-Day Study of GAL-101 in Participants With Mild to Moderate Alzheimer's Disease
This Phase 2a study will evaluate the safety and tolerability of GAL-101 in approximately 100 participants with mild to moderate Alzheimer's disease associated with amyloid-beta pathology.
- Trial name
- SAPHARY (NCT07789873)
- Testing
- GAL-101 Salt
- Volunteers
- 100 people
- Sponsor
- Galimedix Therapeutics Inc
Alzheimer's Disease
Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia
The purpose of this study is to determine the safety, tolerability and effect of JNJ-54861911 on level of amyloid-beta in Cerebrospinal Fluid (CSF) and plasma following 4 weeks of treatment in Japanese participants asymptomatic…
- Trial name
- NCT02360657
- Testing
- JNJ-54861911, 10 mg, JNJ-54861911, 50 mg
- Where
- 2 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Janssen Pharmaceutical K.K.
Geographic Atrophy of the Macula
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina.
- Trial name
- eDREAM (NCT06659549)
- Testing
- GAL-101
- Where
- 24 sites in United States, Armenia and 6 more
- Volunteers
- 110 people
- Sponsor
- Galimedix Therapeutics Inc
Amyloid-beta
Sleep Quality and Amyloid-Beta Kinetics
The purpose of this study is to change the concentration of amyloid-beta in human cerebrospinal fluid (CSF) by modification of sleep efficiency.
- Trial name
- NCT03077620
- Testing
- Suvorexant
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine